APHON Pediatric Chemotherapy-Biotherapy Renewal

greater awareness of the measures necessary to alleviate and remedy the toxicities that do occur. References Becuart, O., Lacotte, J., Malissart, P., Nadal, J., Lesage, C., Guillot, B., & Du Thanh, A. (2019). Myasthenia gravis induced by immune checkpoint inhibitors. Journal of Immunotherapy , 42 (8), 309–312. https://doi.org/10.1097/CJI.0000000000000278 Bhojwani, D., Sabin, N. D., Pei, D., Yang, J. J., Khan, R. B., Panetta, J. C., Krull, K. R., Inaba, H., Rubnitz, J. E., Metzger, M. L., Howard, S. C., Ribeiro, R. C., Cheng, C., Reddick, W. E., Jeha, S., Sandlund, J. T., Evans, W. E., Pui, C.-H., & Relling, M. V. (2014). Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology , 32 (9), 949–959. https://doi.org/10.1200/JCO.2013.53.0808 Corbin, Z. A., Nguyen-Lin, A., Li, S., Rahbar, Z., Tavallaee, M., Vogel, H., Salva, K. A., Wood, G. S., Kim, Y. H., & Nagpal, S. (2017). Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. Journal of Neuro-Oncology , 132 (3), 439–446. https://doi.org/10.1007/s11060-017-2389-9 Frisk, P., Stålberg, E., Strömberg, B., & Jakobson, A. (2001). Painful peripheral neuropathy after treatment with high-dose ifosfamide. Medical and Pediatric Oncology , 37 (4), 379–382. https://doi.org/10.1002/mpo.1210 Gillard, M., Herring, R. A., & Hesselgrave, J. (2019). Toxicity and symptom management. In R.A. Herring (Ed.), The pediatric chemotherapy and biotherapy curriculum (4th ed., pp. 215–216). Association of Pediatric Hematology/Oncology Nurses. Hoy, S. M. (2016). Dinutuximab: A review in high-risk neuroblastoma. Targeted Oncology , 11 (2), 247–253. https://doi.org/10.1007/s11523-016-0420-2 Iyer, N. S., Balsamo, L. M., Bracken, M. B., & Kadan-Lottick, N. S. (2015). Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: A review and meta-analysis. Blood , 126 (3), 346–353. https://doi.org/10.1182/blood-2015-02- 627414 Kennedy, L. B., & Salama, A. K. S. (2020). A review of cancer immunotherapy toxicity. CA: A Cancer Journal for Clinicians , 70 (2), 86–104. https://doi.org/10.3322/caac.21596 McGinty, L., & Kolesar, J. (2017). Dinutuximab for maintenance therapy in pediatric neuroblastoma. American Journal of Health-System Pharmacy , 74 (8), 563–567. https://doi.org/10.2146/ajhp160228 Newman, M. J., & Benani, D. J. (2016). A review of blinatumomab, a novel immunotherapy. Journal of Oncology Pharmacy Practice , 22 (4), 639–645. https://doi.org/10.1177/1078155215618770